Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
Tag: PD-1 inhibitors
Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2. ...
Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) ...
2 Minute Medicine Rewind October 28, 2019
PD-1 blockade in advanced adrenocortical carcinoma 1. Pembrolizumab may provide clinically meaningful anti-tumor activity in the setting of adrenocortical carcinoma, ...
Quick Take: Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Immunotherapies such as anti-PD-1 (anti-programmed cell death 1) and anti-PD-L1 (anti-programmed cell death ligand 1) are effective in treating numerous ...
2 Minute Medicine Rewind June 10, 2018
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
